Effect of Perioperative Sivelstat Administration for Liver Resection

NCT ID: NCT00738348

Last Updated: 2012-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is reported that sivelstat improved and preserved the postoperative renal function in the orthopedic management. Moreover because sivelstat reduced the migration of neutrophil, it improved acute lung injury. During liver resection, Pringle maneuver, clamping the hepatoduodenal ligament, was performed. Pringle maneuver causes reperfusion injury of the liver. We have a hypothesis that sivelstat prevent the warm shock of reperfusion injury of the liver by Pringle maneuver.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Whether the incidence of postoperative morbidities, such as liver failure, renal failure, or congestive heart failure, was reduced by administration of perioperative sivelstat.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2

250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour

Group Type ACTIVE_COMPARATOR

sivelstat

Intervention Type DRUG

sivelstat sodiumhydrate

1

250mL of 5% glucose was injected though the vein at 10mL per an hour

Group Type PLACEBO_COMPARATOR

glucose

Intervention Type DRUG

glucose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sivelstat

sivelstat sodiumhydrate

Intervention Type DRUG

glucose

glucose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sivelstat sodiumhydrate, ONO PHARMACEUTICAL CO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* liver disease which surgical management was indicated

Exclusion Criteria

* weight loss greater than 10 per cent during the previous 6 months, signs of distant metastasis, or of respiratory, renal or heart disease
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kochi University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Takehiro Okabayashi

University

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Takehiro Okabayashi, MD, PhD

Role: STUDY_DIRECTOR

Kochi Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kochi Medical School

Kohasu-Okocho, Nankoku, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Kochi University

Identifier Type: -

Identifier Source: secondary_id

ESAR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.